A Multicenter Randomized Controlled Trial on Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Adults and Children

Brief description of study

The purpose of this study is to determine if the drug hydroxychloroquine is safe for use in humans with COVID-19 and if it works as a treatment for COVID-19 in people who are hospitalized. Specifically, the study seeks to determine whether people treated with hydroxychloroquine go on to have less severe disease. Hydroxychloroquine has been tested and used before in humans with other diseases. It has been given to people with COVID-19, but we do not know if it helps patients with COVID-19 get better, has no effect on their progress, or causes a worse course. Hydroxychloroquine is approved by the FDA for other conditions, but its use for COVID-19 is considered investigational. The research study will compare hydroxychloroquine to a placebo. The placebo looks like hydroxychloroquine but contains no medicine. During this study, you may get the placebo instead of hydroxychloroquine. A placebo is used in research studies to compare the results and side effects of the drug being studied to the results and side effects of taking no medication.

Clinical Study Identifier: s20-00463
ClinicalTrials.gov Identifier: NCT04369742
Principal Investigator: Mark J. Mulligan
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.